PCVX Q2 2024 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$153M

Net Income

-$129M

EPS (Diluted)

$-1.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$121M

Free Cash Flow

-$167M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$101M

Stockholders' Equity

$2.0B

Cash & Equivalents

$519M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$153M	-$87M	-75.5%
Net Income	-$129M	-$68M	-88.3%